Strategic Performance Drivers
Revenue growth of 36% was underpinned by a 40.5% surge in the data applications business, specifically driven by the Insights segment’s data licensing and modeling capabilities.
Management attributes diagnostic outperformance to a 28% unit growth in oncology, fueled by high attach rates for transcriptomic algorithms that assist overworked physicians in real-time decision-making.
The company is successfully transitioning from simple data licensing to strategic AI collaboration, with partners increasingly building proprietary foundation models on the Tempus 500-petabyte database.
A strategic shift is occurring in pharma relationships, moving from single-project engagements to large-scale, multi-year strategic collaborations exceeding $100 million in total contract value.
The hereditary business experienced a temporary slowdown due to difficult year-over-year comparisons following a period of 40% growth, but management expects a return to mid-teens growth in the second half of 2026.
Operational efficiency is improving through a diversified portfolio where high-margin data revenue increasingly offsets the costs of scaling diagnostic volume.
Outlook and Strategic Assumptions
Full-year 2026 revenue guidance was raised to a range of $1.59 billion to $1.60 billion, supported by record visibility into the data and applications pipeline.
Management projects a $500 incremental lift in diagnostic average selling price (ASP) over the next one to two years as more assays receive FDA approval and transition to ADLT status.
The company expects to maintain a 25% top-line compound annual growth rate over the next three years, driven by a mix of volume expansion and reimbursement tailwinds.
MRD volume growth is being intentionally metered to align with reimbursement improvements to protect unit economics and avoid increasing cash burn prematurely.
Expansion into neurology and rare disease is viewed as a long-term growth lever, with a multimillion-dollar Alzheimer’s multimodal model project expected to conclude mid-2026.
Operational Risks and Structural Updates
The company is awaiting an imminent FDA decision on an amendment for the XT assay to cover tumor-only cases, which is critical for accelerating the migration to higher-priced ADLT versions.
Q1 cash flow from operations was impacted by approximately $70 million due to seasonal bonus payouts and the timing of payables, which management expects to normalize in Q2.
Management explicitly stated they have no requirement for alternative financing or additional capital, citing a clear path to positive adjusted EBITDA of $65 million for the year.
Companion diagnostics (CDX) status wins by competitors are viewed as having no material impact on U.S. physician ordering patterns due to existing drug payment structures.
